BioNTech (NASDAQ:BNTX – Get Free Report) had its target price dropped by analysts at HC Wainwright from $150.00 to $145.00 in ...

Investment analysts at HC Wainwright began coverage on shares of Rezolve AI (NASDAQ:RZLV – Get Free Report) in a research ...

Fintel reports that on April 2, 2025, HC Wainwright & Co. upgraded their outlook for Sarepta Therapeutics (NasdaqGS:SRPT) ...

Highlights,Cabaletta Bio receives a favorable evaluation from HC Wainwright.,An institutional review brings renewed focus to ...

H.C. Wainwright analyst Ed Arce maintained a Hold rating on Galectin Therapeutics (GALT – Research Report) today. The company’s shares closed ...

H.C. Wainwright analyst Kevin Dede maintained a Hold rating on Mawson Infrastructure Group (MIGI – Research Report) today. The company’s shares ...

We recently published a list of 10 Firms Outperform Broader Market on Tuesday. In this article, we are going to take a look ...

GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of Natural ...

Q3 2025 Management View CEO Jim Clemmer highlighted strong Q3 performance with total revenue reaching $72 million, reflecting over 9% year-over-year growth. MedTech revenue grew by 22%, with continued ...

The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $10.79, a high estimate of $14.00, and a low estimate of $1.15. A decline of 4.6% from the prior ...